Alkem Laboratories Limited (ALKEM)
Investor Presentation
[Motilal Oswal Conference] Press Release - Q1FY27
- Revenue ₹37.4bn +10.9% y-y; EBITDA ₹7.66bn (margin 20.5%, +3.7% y-y); PAT ₹5.2bn -21.7% y-y
- India sales grew 10.3% with 100 bps outperformance vs IPM at 13.2% growth in Q1FY27
- US sales up 6.5%, non-US international sales surged 34.5% driven by key markets
- Received 5 ANDA approvals in US during Q1FY27
- R&D spend increased to 4.0% of revenue; focus on strengthening core and new growth in MedTech and Biotech
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 ALKEM — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add ALKEM to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Alkem Laboratories Limited
Important.
The summary above is generated automatically from Alkem Laboratories Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.